ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Reverse Split

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon May 25, 2021 1:40pm

135 Views

Post# 33260727

RE:RE:RE:Reverse Split

I believe a Reverse Stock is eminent when the Share Price becomes 0.50 and above. There are too many outstanding Shares and for those Buying and Holding now will benefit from a Reverse Stock Split. Would you rather Buy Shares at 0.15 or 0.50 ? Obviously the lower amount is better for the Shareholder.

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs